We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

83 hedge funds and large institutions have $298M invested in Supernus Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

380% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 5

45% more call options, than puts

Call options by funds: $10.8M | Put options by funds: $7.46M

30% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 20

30% more funds holding

Funds holding: 64 → 83 (+19)

28% more capital invested

Capital invested by funds: $234M → $298M (+$64.9M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
83
Holders Change
+19
Holders Change %
+29.69%
% of All Funds
2.4%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
24
Increased
26
Reduced
20
Closed
5
Calls
$10.8M
Puts
$7.46M
Net Calls
+$3.33M
Net Calls Change
+$3.13M

Top Buyers

Rank Fund Capital Flow
1
MRM
Michael R. Murphy
+$12.4M
2
NC
Northpointe Capital
Michigan
+$9.85M
3
JGC
J. Goldman & Co
New York
+$2.82M
4
Bank of America
Bank of America
North Carolina
+$2.26M
5
EAM
Eventide Asset Management
Massachusetts
+$1.98M

Top Sellers

Rank Fund Capital Flow
1
HVC
Healthcare Value Capital
New Jersey
-$8.69M
2
OHCM
Orchard Hill Capital Management
New York
-$8.59M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.35M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.62M
5
Ameriprise
Ameriprise
Minnesota
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$1.36M +$1.4M +152,442 New
RP
27
Reinhart Partners
Wisconsin
$1.36M -$53.3K -5,789 -4%
TCM
28
Tekla Capital Management
Massachusetts
$1.26M – – –
PAM
29
Panagora Asset Management
Massachusetts
$1.24M -$10.5K -1,145 -0.8%
TD Asset Management
30
TD Asset Management
Ontario, Canada
$1.03M +$87.5K +9,500 +9%
HVC
31
Healthcare Value Capital
New Jersey
$954K -$8.69M -944,010 -90%
TAM
32
Tocqueville Asset Management
New York
$934K -$9.21K -1,000 -0.9%
IHM
33
Iguana Healthcare Management
New York
$894K +$921K +100,000 New
Geode Capital Management
34
Geode Capital Management
Massachusetts
$764K +$53.6K +5,819 +7%
CS
35
Credit Suisse
Switzerland
$757K -$51.4K -5,581 -6%
TCIM
36
TIAA CREF Investment Management
New York
$744K +$221K +23,989 +41%
Citadel Advisors
37
Citadel Advisors
Florida
$715K +$599K +64,997 +435%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$696K +$151K +16,399 +27%
DCM
39
Driehaus Capital Management
Illinois
$609K +$628K +68,149 New
BIM
40
BlackRock Investment Management
Delaware
$487K +$96K +10,420 +24%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$476K -$3.35M -363,290 -87%
AL
42
Airain Ltd
Guernsey
$459K +$473K +51,395 New
BCM
43
Bridgeway Capital Management
Texas
$447K – – –
BL
44
Bolton LP
Connecticut
$447K +$460K +50,000 New
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$432K +$454K +49,300 New
WAM
46
Wolverine Asset Management
Illinois
$387K +$170K +18,500 +74%
ProShare Advisors
47
ProShare Advisors
Maryland
$379K +$242K +26,327 +164%
GIP
48
Granite Investment Partners
California
$351K +$362K +39,267 New
Millennium Management
49
Millennium Management
New York
$337K -$489K -53,049 -58%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$329K +$67.2K +7,300 +25%
1
2
3 4

SUPN Hedge Fund Activity: Q1 2014 in Review

83 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2014, worth a combined $298M — up 28% from $234M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SUPN positions and 5 closed out — a net gain of 19 holders — while 26 added to existing stakes and 20 trimmed.

The largest buyer was Michael R. Murphy, opening a new position worth an estimated $12.4M. The largest seller was Healthcare Value Capital, cutting an estimated $8.69M.

  • 83 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2014, up from 64 in Q4 2013.
  • Funds reported $298M of Supernus Pharmaceuticals stock for Q1 2014, up 28% quarter-over-quarter.
  • 24 funds opened new Supernus Pharmaceuticals positions in Q1 2014 and 5 closed out, a net change of +19 holders.
  • The largest Supernus Pharmaceuticals buyer in Q1 2014 was Michael R. Murphy, an estimated $12.4M added.
  • The largest Supernus Pharmaceuticals seller in Q1 2014 was Healthcare Value Capital, an estimated $8.69M sold.

Based on aggregated 13F filings for Q1 2014.